<DOC>
	<DOCNO>NCT01466387</DOCNO>
	<brief_summary>This study compare safety immunogenicity profile several travel vaccine give alone concomitantly MenACWY-CRM healthy adult .</brief_summary>
	<brief_title>A Phase 3b , Randomized , Open-Label Study Evaluate Safety Immunogenicity Select Travel Vaccines When Administered Concomitantly With MenACWY Adults</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Typhoid Fever</mesh_term>
	<mesh_term>Yellow Fever</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female male subject must healthy must : 1 . Between 18 60 year age inclusive give write informed consent ; 2 . Available visit telephone call schedule study ; 3 . In good health determine medical history , physical examination clinical judgment investigator ; 4 . For female subject , negative urine pregnancy test . Individuals eligible enrol study : 1. breastfeeding ; 2. personal history Neisseria meningitidis infection , typhoid fever , rabies , flavivirus infection ( e.g. , Japanese encephalitis , tickborne encephalitis , yellow fever , dengue fever , West Nile virus infection ) ; 3. immunize study vaccine within last five year determine medical history and/or vaccination card ; 4. receive investigational agent vaccine within 30 day prior enrollment expect receive investigational agent vaccine prior completion study ; 5. receive live license vaccine within 30 day inactive vaccine within 15 day prior enrollment receipt license vaccine anticipate study period . ( Exception : Influenza vaccine may administer 15 day prior study immunization le 15 day study immunization ) ; 6. receive antimalaria drug , 2 month prior study ; 7. experience , within 7 day prior enrollment , significant acute infection ( example require systemic antibiotic treatment antiviral therapy ) experience fever ( define body temperature ≥ 38°C ) within 3 day prior enrollment ; 8. serious acute , chronic progressive disease : history cancer complicate diabetes mellitus advanced arteriosclerotic disease autoimmune disease HIV infection AIDS blood dyscrasia congestive heart failure renal failure severe malnutrition ( Note : Subjects mild asthma eligible enrollment . Subjects moderate severe asthma require routine use inhale systemic corticosteroid eligible enrollment ) ; 9. epilepsy , progressive neurological disease history GuillainBarre syndrome ; 10. history anaphylaxis , serious vaccine reaction , allergy vaccine component , include limited latex allergy , egg allergy , antibiotic allergy , chicken protein gelatin allergy ; 11. know suspected impairment/alteration immune function , either congenital acquire result ( example ) : receipt immunosuppressive therapy within 30 day prior enrollment ( systemic corticosteroid administer 5 day , daily dose &gt; 1 mg/kg/day prednisone equivalent 30 day prior enrollment , cancer chemotherapy ) ; receipt immunostimulants ; receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 90 day prior enrollment full length study ; 12. know bleeding diathesis , condition may associate prolonged bleeding time ; 13. myasthenia gravis ; thyroid thymic disorder , 14. condition , opinion investigator , might interfere evaluation study objective ; 15. part study personnel close family member conduct study . 16. longterm stay ( ≥ 1 month ) plan Africa , Latin America , Asia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Adults</keyword>
	<keyword>international travel vaccination</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>meningococcal meningitis</keyword>
	<keyword>typhoid</keyword>
	<keyword>yellow fever</keyword>
	<keyword>rabies</keyword>
	<keyword>Japanese encephalitis</keyword>
</DOC>